Practicality and potential restrictions of unresectable hepatocellular carcinoma prognostic index
- PMID: 36125257
- PMCID: PMC9701471
- DOI: 10.1002/hep4.2093
Practicality and potential restrictions of unresectable hepatocellular carcinoma prognostic index
Conflict of interest statement
PC received grants from Gilead Sciences and AbbVie. MRB consults for Janssen and Roche. She consults, advises, and is on the speakers' bureau for Gilead. She advises and is on the speakers' bureau for AbbVie. She is also on the speakers' bureau for EISAI‐MSD.
Comment on
-
Proposal and Validation of a Novel Scoring System for Hepatocellular Carcinomas Beyond Curability Borders.Hepatol Commun. 2022 Mar;6(3):633-645. doi: 10.1002/hep4.1836. Epub 2021 Nov 9. Hepatol Commun. 2022. PMID: 34751001 Free PMC article.
-
Response to immunotherapy plus anti-angiogenic agent combination challenges hepatocellular carcinoma prognostic scores.Hepatol Commun. 2022 Dec;6(12):3595-3596. doi: 10.1002/hep4.2047. Epub 2022 Jul 12. Hepatol Commun. 2022. PMID: 35819258 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
